Literature DB >> 32958552

Adalimumab-associated psoriasiform rash in an African-American patient.

Yusuf Chao1, Jake Hutto2, Neil Keshvani2, Una E Makris2.   

Abstract

Entities:  

Keywords:  dermatology; drugs: musculoskeletal and joint diseases; immunological products and vaccines; immunology; rheumatology

Mesh:

Substances:

Year:  2020        PMID: 32958552      PMCID: PMC7507334          DOI: 10.1136/bcr-2020-236376

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.
  6 in total

1.  Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.

Authors:  Andrew F Alexis; Paul Blackcloud
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

Review 2.  Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.

Authors:  Paul Sator
Journal:  Ther Adv Chronic Dis       Date:  2018-05-22       Impact factor: 5.091

Review 3.  Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.

Authors:  Gabrielle Brown; Eva Wang; Argentina Leon; Monica Huynh; Mackenzie Wehner; Rebecca Matro; Eleni Linos; Wilson Liao; Anna Haemel
Journal:  J Am Acad Dermatol       Date:  2016-10-05       Impact factor: 11.527

4.  Psoriasiform reactions to anti-tumor necrosis factor α therapy.

Authors:  Khang Nguyen; Ruth Ann Vleugels; Nicole F Velez; Joseph F Merola; Abrar A Qureshi
Journal:  J Clin Rheumatol       Date:  2013-10       Impact factor: 3.517

5.  TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Authors:  Sara Jiayang Li; Lourdes M Perez-Chada; Joseph F Merola
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2018-11-21

6.  TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.

Authors:  Curdin Conrad; Jeremy Di Domizio; Alessio Mylonas; Cyrine Belkhodja; Olivier Demaria; Alexander A Navarini; Anne-Karine Lapointe; Lars E French; Maxime Vernez; Michel Gilliet
Journal:  Nat Commun       Date:  2018-01-02       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.